Dr. Jacqueline Lui, President of Eagle IP Group, gave a talk titled “Patent War : A Case Study on the Viagra China Patent” at the HKBMIA Happy Hour event.
Our Past Events
Recommended Insights
China Top 10 Cases of 2020 – CNIPA Upholds Second Medical Use Patent from University of Bordeaux
24 May 2021The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
Read more >
China’s Newest Examination Guidelines: Post-Filing Supplemental Data for Compounds (Part I)
28 April 2021Post-filing data in China has been a constant issue for many patent practitioners around the world. Examiners seem to require it often, and yet the rules regarding when it is acceptable have seemed much stricter than other jurisdictions worldwide. In fact, we tried to summarize the latest state of the law in an earlier blog […]
Read more >
New Remedy in China for Fixing "Errors" in a Patent Application: Incorporation by Reference
21 March 2024Background As mentioned in our earlier article, the Implementation Regulations of the Chinese Patent Law (“Regulations”, similar to the CFR in the US) were approved in November, and the CNIPA finally made public the full text of the Regulations just before the arrival of the New Year. At the same time, the CNIPA also released the new […]
Read more >
Everything you need to know about Patent Term Adjustment (PTA) in China
7 May 2024We previously discussed patent term compensation for patent office delay (‘Patent Term Adjustment’ or ‘PTA’) when such new system was introduced in the Fourth Amendment of the Chinese Patent Law (2020), as well as in the different versions of the Draft Examination Guidelines released in 2021 and 2022. In this article, we consolidate everything you need to […]
Read more >